Pharma

Your Article Summary

See Latest Articles

ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial
Current Medical Research and Opinion, 08/18/09

Dusing R et al. – ACE inhibitor/ARB combinations showed equivocal effects on clinical outcomes. DRI/ACE inhibitor and DRI/ARB combinations reduced markers of organ damage, but longer–term trials are required to establish whether more complete renin––angiotensin––aldosterone system control with aliskiren–based therapy translates into improved outcome benefits.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

 See all of Drug Trials